July 2013 - FILM-Users - imperial.ac.uk

[FILM-Users 00388] COMMERCIAL Fwd: Save 15% on ibidi’s NEW µ-Slide 2 well Ph+ and µ-Slide 4 well Ph+
by Martin Spitaler 05 Jul '13

05 Jul '13

-------- Original Message -------- Subject: Save 15% on ibidi’s NEW µ-Slide 2 well Ph+ and µ-Slide 4 well Ph+ Date: Tue, 2 Jul 2013 11:34:10 +0200 From: ibidi cells in focus <events(a)ibidi.de> To: <m.spitaler(a)imperial.ac.uk> Wird diese Nachricht nicht richtig dargestellt, klicken Sie bitte *hier* <http://13457.seu.cleverreach.com/m/6201015/0-c0fcce3f091a29b1c87a7baa3fb125…>. load images *Get a 15% Introductory Discount on ibidi's Latest Innovation!* *µ-Slide 2 well^Ph+ <http://13457.seu.cleverreach.com/c/11401239/b683f5ae3bd6> and µ-Slide 4 well^Ph+ <http://13457.seu.cleverreach.com/c/11401240/b683f5ae3bd6>* * * *Excellent Phase Contrast Over the Entire Well of the Microscopy Chamber!* * * *Test Now <http://13457.seu.cleverreach.com/c/11401241/b683f5ae3bd6> with Your Experiments!* *Why are these imaging chambers superior?* * *No meniscus at the air-water interface* * *Easy handling and cell culturing* * *High-resolution microscopy through a coverslip-like bottom* * *Excellent cell growth on tissue culture treated surface* *Applications:* * *Cultivation and microscopy of cell cultures* * *High-end fluorescence microscopy* * *Transfection <http://13457.seu.cleverreach.com/c/11401243/b683f5ae3bd6>**assays* * *Live cell imaging <http://13457.seu.cleverreach.com/c/11401244/b683f5ae3bd6>**over extended time periods * Ordering Information: *Cat. No. * *Description* *Pcs./Box * *Discount* *µ-Slide 2 well^Ph+ <http://13457.seu.cleverreach.com/c/11401239/b683f5ae3bd6>* 80296 µ-Slide 2 well^Ph+ , ibiTreat, tissue culture treated, sterile 15 15% 80291 µ-Slide 2 well^Ph+ , hydrophobic, uncoated, sterile 15 15% *µ-Slide 4 well^Ph+ <http://13457.seu.cleverreach.com/c/11401240/b683f5ae3bd6>* 80446 µ-Slide 4 well^Ph+ , ibiTreat, tissue culture treated, sterile 15 15% 80441 µ-Slide 4 well^Ph+ , hydrophobic, uncoated, sterile 15 15% / This offer is valid until September 30, 2013. It cannot be combined with other offers or discounts./ *Order a FREE SAMPLE <http://13457.seu.cleverreach.com/c/11401245/b683f5ae3bd6> to test ibidi's µ-Slide 2 well^Ph+ and µ-Slide 4 well^Ph+ with your experiments.* Wenn Sie diese E-Mail (an: m.spitaler(a)imperial.ac.uk) nicht mehr empfangen möchten, können Sie diese *hier* <http://13457.seu.cleverreach.com/rmftlp.php?cid=0&mid=6201015&h=0-b683f5ae3…> abbestellen. ibidi GmbH Am Klopferspitz 19 82152 Planegg-Martinsried Deutschland www.ibidi.com events(a)ibidi.de Geschäftsführer: Dr. Roman Zantl, Dr. Valentin Kahl Handelsregister: Amtsgericht München, Registernr.: HRB 135854 Ust.Ident.Nr.: DE 215 296 022 <http://13457.seu.cleverreach.com/c/11401246/b683f5ae3bd6>

1 0

[FILM-Users 00387] Fwd: Talk on multiphoton NADH and FAD imaging on 8th July
by Martin Spitaler 05 Jul '13

05 Jul '13

...forwarded for your information.... Martin -------- Original Message -------- Subject: Talk on multiphoton NADH and FAD imaging on 8th July Date: Thu, 27 Jun 2013 17:41:01 +0100 From: Dunsby, Christopher W <christopher.dunsby(a)imperial.ac.uk> To: Spitaler, Martin <m.spitaler(a)imperial.ac.uk> Dear Martin, You might be interested in the talk below from Alex Walsh who is in Melissa Skala's group at Vanderbilt University. It is scheduled for 1100 on Monday 8^th July in the Optics Reading Room (Blackett 613). best regards, Chris *From:*alexandra.j.walsh@vanderbilt.edu [mailto:alexandra.j.walsh@vanderbilt.edu] *On Behalf Of *Alex Walsh *Sent:* 26 June 2013 21:43 *To:* Dunsby, Christopher W *Cc:* Kelly, Douglas J; French, Paul (PHOT) M W (Photonics); Melissa Skala *Subject:* Re: Alex's July visit Yes, title and abstract are below. Optical metabolic imaging predicts anti-cancer therapeutic response The drug combination that is chosen for cancer patients is determined from histological markers of receptor expression. Unfortunately, many patients do not respond to chemotherapy, and therefore face a greater risk of recurrence and death. No current technologies can accurately predict individual tumor response to particular drugs. Cellular metabolism is a potentially powerful marker of tumor response to treatment, because the oncogenic drivers targeted by therapeutic agents often regulate cellular metabolism. In this study, we demonstrate the sensitivity of optical metabolic imaging to predict therapeutic response in xenografts /in vivo/,//and//in primary patient tumor derived organoids, in both breast cancer and pancreatic cancer models. We utilize mulitphoton fluorescence intensity and fluorescence lifetime imaging to probe cellular NADH and FAD, two coenzymes of metabolism. Endpoints of cellular metabolism include the optical redox ratio (NADH fluorescence intensity divided by that of FAD) the mean fluorescence lifetime of NADH, and the mean fluorescence lifetime of FAD. Upon treatment with estrogen receptor inhibitors and human epidermal growth factor receptor inhibitors, the redox ratio of responsive tumors decreases (p<0.001) and is further reduced when effective therapies are combined (p<0.001). Furthermore, the NADH fluorescence lifetime decreases in organoids treated with human epidermal growth factor receptor inhibitors (p<0.05). With these findings, optical metabolic imaging shows potential for development into a high-throughput screen to test the efficacy of a panel of drugs to direct clinical therapy selection and expedite pre-clinical studies. Alex Walsh

1 0

[FILM-Users 00369] IMPORTANT, QUICK RESPONSE NEEDED PLEASE: BBSRC Advanced Life Sciences Research Technologies initiative (ALERT 13) - research equipment call
by Martin Spitaler 02 Jul '13

02 Jul '13

Dear microscopists, as you might have seen, the BBSRC has just announced a dedicated call for *_instrumentation to be deployed on a multi-project/multi-use basis_* (see below) - an excellent opportunity to upgrade our facility to respond to your latest needs. The funding (£250-750k) would cover *one* new bit of high-end equipment, so we need to decide where strongest needs will be in the coming years. That's where your input is needed: Please let me know what kind of experiments you would like to do in the future that you can't do currently in FILM, where major investment would make a big difference to your research. Ideas put up before were a commercial super-resolution microscope, high-throughput microscope, dedicated intravital microscope - but feedback on any unmet needs is appreciated. The deadline is soon and it's a busy time of the year, so *please let me know within a week* what your thoughts are (please reply to me personally, not the whole mailing list). Looking forward to your input, good imaging, Martin *From: *<Nadal>, Rebecca C <r.nadal(a)imperial.ac.uk <mailto:r.nadal@imperial.ac.uk>> *Date: *Wednesday, 29 May 2013 15:32 *Subject: *BBSRC Advanced Life Sciences Research Technologies initiative (ALERT 13) - research equipment call Dear all, I can confirm that the BBSRC capital equipment call has now gone live, please see http://www.bbsrc.ac.uk/funding/opportunities/2013/alert13.aspx for full details. The closing date for applications is *4pm on 23 July 2013.* BBSRC are inviting applications for research grants from *eligible researchers with a strong track record of research in the BBSRC remit*, to purchase items of *advanced research equipment* via this Advanced Life Sciences Research Technology 2013 (ALERT 13) call. The capital equipment budget for this call is approximately £8M. Applications for equipment funding, which will typically be in the range of £250k-£750k excl. VAT although higher value applications will be considered with prior agreement, and must enhance the capability of the UK research base in areas of science in the BBSRC remit. Applications will typically be from groups of researchers in one or more eligible institutions, for_*instrumentation to be deployed on a multi-project/multi-use basis*_. When BBSRC recently visited they indicated that they would like to see some degree of coordination of bids by universities, but the details of this internal coordination are still to be confirmed. I'm guessing that a number of applicants may have already started preparing bids following the pre-announcement that you received directly from BBSRC and/or from me. Please feel free to forward as appropriate, and for now please encourage any potential applicants to contact me (r.nadal(a)imperial.ac.uk <mailto:r.nadal@imperial.ac.uk>) to alert me about their bid. Many thanks. Best wishes, Becky. Dr Rebecca Nadal Strategic Research Coordinator Faculty of Natural Sciences Imperial College London South Kensington Campus London SW7 2AZ Email: r.nadal(a)imperial.ac.uk <mailto:r.nadal@imperial.ac.uk> Tel: 020 7594 8909 Mobile: 07714 051234

1 1